動物用ワクチンの市場：種類（豚、家禽、家畜、コンパニオンアニマル）、技術（生消毒、不活化、毒素）、投与経路（注射、鼻腔内）、流通チャネル（病院、クリニック）-2027年までの世界予測

Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Injection, Intranasal), Distribution Channel (Hospitals, Clinics) - Global Forecast to 2027

動物用ワクチンの世界市場は、2022年の81億米ドルから2027年には108億米ドルに達すると予測され、予測期間中の年平均成長率は5.9%に達するとされています。インドや中国などの新興国では、ペット保険産業は発展途... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年4月7日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	293	361	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

動物用ワクチンの世界市場は、2022年の81億米ドルから2027年には108億米ドルに達すると予測され、予測期間中の年平均成長率は5.9%に達するとされています。インドや中国などの新興国では、ペット保険産業は発展途上の段階にある。可処分所得の増加やペットへの支出額の増加により、ペット保険の導入が進み、動物医療業界を支えるものと期待されます。

家畜用ワクチン市場では、ウシ用ワクチン分野が大きなシェアを占めている

2021年の家畜ワクチン市場では、ウシワクチン分野がより大きなシェアを占めています。また、このセグメントは予測期間中、より高いCAGRで成長すると推定されます。このセグメントの成長は、主に肉と牛乳の需要の増加と、家畜の病気の予防に関する意識の高まりに起因していると考えられます。

予測期間中、組み換えワクチンのCAGRが最も高く成長する

技術別では、遺伝子組み換えワクチンが予測期間中に最も高いCAGRで成長すると考えられます。組み換えワクチンの主な利点として、アジュバントが不要であること、周囲温度で生存可能な安定性があることが挙げられます。また、これらのワクチンは病原体の混入がなく、ワクチン接種後の反応もなく、高い安全性を提供します。

動物用ワクチンの世界市場において、北米が第2位のシェアを占める

2021年、北米は世界の動物用ワクチン市場のシェアを占めています。動物人口の増加や動物疾病の蔓延の拡大、動物用ワクチンの認知度の向上、動物製品の需要増などが、北米の動物用ワクチン市場の成長を促進する主な要因として期待されています。医療費の増加に加え、ペット健康保険業界も急成長しています。

動物用ワクチン市場の主要参入企業のプロファイルのブレークアップ：
- 企業タイプ別：ティア1 - 60%、ティア2 - 30%、ティア3 - 10
- 役職別Cレベル：30％、ディレクターレベル：50％、その他：20
- 地域別北米：45％、欧州：15％、アジア太平洋：25％、中近東：5％、中南米：10％。

動物用ワクチン市場の主要企業は、Zoetis, Inc（米国）、Merck & Co, Inc（米国）、Boehringer Ingelheim International GmbH（ドイツ）、Elanco Animal Health（米国）、Virbac（フランス）です。
調査範囲
本レポートでは、動物用ワクチン市場を分析し、種類、疾患、技術、投与経路、流通チャネル、地域などのさまざまなセグメントに基づいて、市場規模や今後の成長可能性を推定することを目的としています。また、市場で入手可能な様々な動物用ワクチンの製品ポートフォリオマトリックスも掲載しています。また、本レポートでは、本市場の主要企業の競争分析も行っており、企業プロファイル、製品提供、主要な市場戦略も併せて掲載しています。
本レポートを購入する理由
本レポートは、動物用ワクチン市場全体とサブセグメントの収益数の最も近い近似値に関する情報を提供することで、本市場のマーケットリーダー/新規参入者に貢献します。本レポートは、利害関係者が競争環境を理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、および機会に関する情報を提供します。
本レポートは、以下のポイントに関する洞察を提供します：

- 動物用ワクチン市場の成長に影響を与える主な促進要因（コンパニオンアニマル人口の増加、人獣共通感染症の発生率の上昇、各種政府機関および動物協会による取り組み、動物由来の食品需要の増加、ペット保険需要の増加、動物医療費の増加）、抑制要因（ワクチンの保管コストの高さ、ペットケア費用の上昇）、機会（技術進歩、未開拓の新興市場）、課題（不十分な監視・報告システム、新興国の動物医療意識の欠如）の解析
- 製品開発/イノベーション：動物用ワクチン市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察
- 市場開拓：タイプ、疾患、技術、投与経路、流通チャネル、地域別に、有利な新興市場に関する包括的な情報。
- 市場の多様化：世界の動物用医薬品市場における新製品や製品の強化、成長地域、最近の開発、投資に関する情報を網羅的に提供します。
- 競争力のある評価：動物用ワクチンの世界市場におけるZoetis, Inc.（米国）、Merck & Co, Inc.（米国）、Boehringer Ingelheim International GmbH（ドイツ）、Elanco Animal Health（米国）、Virbac（フランス）などの主要企業の市場シェア、成長戦略、製品提供、競合リーダーシップマッピング、能力について詳細に評価します。

ページTOPに戻る

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 28
TABLE 1 STANDARD CURRENCY CONVERSION RATES 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 29
1.7 SUMMARY OF CHANGES 29
1.8 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY DATA 33
FIGURE 2 PRIMARY SOURCES 33
2.1.2.1 Key data from primary sources 34
2.1.2.2 Key industry insights 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 35
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION 36
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS, BY END USER, DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION 37
FIGURE 6 VETERINARY VACCINES MARKET: SUPPLY-SIDE MARKET SIZE ESTIMATION 37
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: MERCK & CO., IN. 38
FIGURE 8 VETERINARY VACCINES MARKET: SUPPLY-SIDE ANALYSIS OF LEADING COMPANIES (2021) 39
FIGURE 9 VETERINARY VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 40
FIGURE 10 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 40
FIGURE 11 TOP-DOWN APPROACH 41

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY 42
2.4 MARKET SHARE ANALYSIS 43
2.5 STUDY ASSUMPTIONS 43
2.6 RISK ASSESSMENT 43
TABLE 2 VETERINARY VACCINES MARKET: RISK ASSESSMENT ANALYSIS 43
2.7 LIMITATIONS 44
2.7.1 METHODOLOGY-RELATED LIMITATIONS 44
2.7.2 SCOPE-RELATED LIMITATIONS 44
2.8 VETERINARY VACCINES MARKET: RECESSION IMPACT 44
3 EXECUTIVE SUMMARY 45
FIGURE 13 VETERINARY VACCINES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 45
FIGURE 14 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 46
FIGURE 15 VETERINARY VACCINES MARKET, BY DISEASE, 2022 VS. 2027 (USD MILLION) 46
FIGURE 16 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION) 47
FIGURE 17 VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION) 47
FIGURE 18 VETERINARY VACCINES MARKET: GEOGRAPHICAL SNAPSHOT 48
4 PREMIUM INSIGHTS 49
4.1 VETERINARY VACCINES MARKET OVERVIEW 49
FIGURE 19 RISING GROWTH IN COMPANION ANIMAL POPULATION TO DRIVE MARKET 49
4.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY (2021) 50
FIGURE 20 LIVE ATTENUATED VACCINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 50
4.3 VETERINARY VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
FIGURE 21 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 51
4.4 VETERINARY VACCINES MARKET, BY REGION 52
FIGURE 22 ASIA PACIFIC REGION TO DOMINATE MARKET DURING FORECAST PERIOD 52
4.5 VETERINARY VACCINES MARKET: DEVELOPED VS. EMERGING ECONOMIES 52
FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 24 VETERINARY VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Growth in companion animal population 54
TABLE 3 EUROPEAN PET POPULATION, BY ANIMAL, 2016–2022 (MILLION) 55
5.2.1.2 Rising incidence of zoonotic diseases 55
TABLE 4 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2009–2019) 56
5.2.1.3 Initiatives by various government agencies and animal associations 56
5.2.1.4 Rising demand for animal-derived food products 57
TABLE 5 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK (DEVELOPED VS. EMERGING MARKETS) 57
TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 58
TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 58
5.2.1.5 Growing demand for pet insurance and rising animal health expenditure 58
TABLE 8 US: AVERAGE PREMIUMS PAID (2019–2021) 59
FIGURE 25 CANADA: AVERAGE ANNUAL PREMIUMS, 2017–2021 59
FIGURE 26 US: PET INDUSTRY EXPENDITURE, 2010–2021 60
TABLE 9 US: BREAKDOWN OF PET INDUSTRY EXPENDITURE, 2020 VS. 2021 (USD BILLION) 60
TABLE 10 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2021 (USD MILLION) 61
5.2.2 RESTRAINTS 61
5.2.2.1 High storage cost of vaccines 61
5.2.2.2 Rising pet care costs 61
FIGURE 27 US: BASIC ANNUAL EXPENSES FOR DOGS AND CATS, 2021 62
5.2.3 OPPORTUNITIES 62
5.2.3.1 Technological advancements 62
5.2.3.2 Untapped emerging markets 62
5.2.4 CHALLENGES 63
5.2.4.1 Inadequate surveillance and reporting systems 63
5.2.4.2 Lack of animal healthcare awareness in emerging countries 63
5.3 INDUSTRY TRENDS 64
5.3.1 GROWING SCALE OF VETERINARY BUSINESSES 64
5.4 REGULATORY ANALYSIS 64
5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.4.2 US 67
5.4.3 EUROPE 67
5.4.4 REST OF THE WORLD 68
5.5 VALUE CHAIN ANALYSIS 69
FIGURE 28 VETERINARY VACCINES MARKET: VALUE CHAIN ANALYSIS 70
5.6 SUPPLY CHAIN ANALYSIS 70
FIGURE 29 VETERINARY VACCINES MARKET: SUPPLY CHAIN ANALYSIS 71
5.7 ECOSYSTEM ANALYSIS 72
FIGURE 30 VETERINARY VACCINES MARKET: ECOSYSTEM ANALYSIS 72
5.8 PORTER’S FIVE FORCES ANALYSIS 73
TABLE 12 PORTER’S FIVE FORCES ANALYSIS 73
5.8.1 THREAT OF NEW ENTRANTS 73
5.8.2 THREAT OF SUBSTITUTES 73
5.8.3 BARGAINING POWER OF SUPPLIERS 74
5.8.4 BARGAINING POWER OF BUYERS 74
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.9 PATENT ANALYSIS 74
5.9.1 PATENT PUBLICATION TRENDS FOR VETERINARY VACCINES 74
FIGURE 31 PATENT PUBLICATION TRENDS (JANUARY 2013–MARCH 2023) 75
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS 75
FIGURE 32 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINES PATENTS (JANUARY 2013–MARCH 2023) 76
FIGURE 33 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY VACCINES PATENTS (JANUARY 2013–MARCH 2023) 77
5.10 TECHNOLOGY ANALYSIS 77
5.11 INDICATIVE PRICING MODEL ANALYSIS 77
TABLE 13 AVERAGE SELLING PRICE OF VETERINARY VACCINES 77
5.11.1 AVERAGE SELLING PRICE TRENDS 78
5.12 KEY CONFERENCES AND EVENTS (2023–2025) 78
TABLE 14 VETERINARY VACCINES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 78
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY VACCINES 79
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY VACCINES 79
5.13.2 BUYING CRITERIA 80
FIGURE 35 KEY BUYING CRITERIA FOR VETERINARY VACCINES 80
TABLE 16 KEY BUYING CRITERIA FOR VETERINARY VACCINES 80
6 VETERINARY VACCINES MARKET, BY TYPE 81
6.1 INTRODUCTION 82
TABLE 17 VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 82
6.2 LIVESTOCK VACCINES 82
TABLE 18 LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 83
TABLE 19 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
6.2.1 BOVINE VACCINES 84
6.2.1.1 Bovine vaccines segment to dominate market 84
TABLE 20 BOVINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.2.2 SMALL RUMINANT VACCINES 85
6.2.2.1 Small ruminant vaccines segment to register lower growth in livestock vaccines market 85
TABLE 21 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
6.3 PORCINE VACCINES 86
6.3.1 SECOND-LARGEST MARKET DURING FORECAST PERIOD 86
TABLE 22 PORCINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.4 POULTRY VACCINES 87
6.4.1 INCREASED PRODUCTION AND REARING OF POULTRY TO DRIVE MARKET GROWTH 87
TABLE 23 POULTRY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
6.5 COMPANION ANIMAL VACCINES 87
TABLE 24 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 25 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
6.5.1 CANINE VACCINES 89
6.5.1.1 Canine vaccines segment to dominate companion animal vaccines market during forecast period 89
TABLE 26 CANINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
6.5.2 FELINE VACCINES 90
6.5.2.1 Rising prevalence of zoonotic diseases to drive demand for feline vaccines 90
TABLE 27 FELINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
6.6 AQUACULTURE VACCINES 91
6.6.1 VACCINATION PLAYS CRUCIAL ROLE IN COMMERCIAL FISH FARMING 91
TABLE 28 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
6.7 OTHER ANIMAL VACCINES 92
TABLE 29 OTHER COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
7 VETERINARY VACCINES MARKET, BY DISEASE 93
7.1 INTRODUCTION 94
TABLE 30 VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 94
7.2 PORCINE DISEASES 94
7.2.1 PORCINE CIRCOVIRUS II TO ACCOUNT FOR LARGEST SHARE OF PORCINE VACCINES MARKET 94
TABLE 31 PORCINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 95
TABLE 32 PORCINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 POULTRY DISEASES 96
7.3.1 INFECTIOUS BRONCHITIS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF POULTRY VACCINES MARKET 96
TABLE 33 POULTRY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 96
TABLE 34 POULTRY DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.4 LIVESTOCK DISEASES 97
TABLE 35 LIVESTOCK VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 97
TABLE 36 LIVESTOCK DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 98
7.4.1 BOVINE DISEASES 98
7.4.1.1 Foot-and-mouth disease segment to account for largest share of bovine vaccines market 98
TABLE 37 BOVINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 99
TABLE 38 BOVINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 99
7.4.2 SMALL RUMINANT DISEASES 100
7.4.2.1 Clostridial disease segment to account for largest share of small ruminant vaccines market 100
TABLE 39 SMALL RUMINANT VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 100
TABLE 40 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 101
7.5 COMPANION ANIMAL DISEASES 101
TABLE 41 COMPANION ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 101
TABLE 42 COMPANION ANIMAL DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 102
7.5.1 CANINE DISEASES 102
7.5.1.1 Canine rabies segment to account for largest share of canine vaccines market 102
TABLE 43 CANINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 103
TABLE 44 CANINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
7.5.2 FELINE DISEASES 104
7.5.2.1 Feline viral rhinotracheitis segment to grow at highest CAGR during forecast period 104
TABLE 45 FELINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 104
TABLE 46 FELINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
7.6 AQUACULTURE DISEASES 106
7.6.1 VACCINES IN AQUACULTURE MAJORLY DEVELOPED FOR SALMONIDS, CATFISH, AND SHRIMP 106
TABLE 47 AQUACULTURE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
8 VETERINARY VACCINES MARKET, BY TECHNOLOGY 107
8.1 INTRODUCTION 108
TABLE 48 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 108
8.2 LIVE ATTENUATED VACCINES 108
8.2.1 LIVE ATTENUATED VACCINES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 108
TABLE 49 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109

8.3 INACTIVATED VACCINES 110
8.3.1 RISING NEED TO DEVELOP ARTIFICIAL IMMUNITY AGAINST DISEASES FROM NON-LIVING PATHOGENS TO DRIVE GROWTH 110
TABLE 50 INACTIVATED VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 110
8.4 TOXOID VACCINES 111
8.4.1 TOXOID VACCINES USED WHEN BACTERIAL TOXINS CAUSE ILLNESS 111
TABLE 51 TOXOID VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
8.5 RECOMBINANT VACCINES 112
8.5.1 ADVANTAGES ASSOCIATED WITH RECOMBINANT VACCINES TO DRIVE DEMAND 112
TABLE 52 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112
8.6 OTHER VACCINES 113
TABLE 53 OTHER VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 113
9 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 114
9.1 INTRODUCTION 115
TABLE 54 ROUTES OF ADMINISTRATION OF MAJOR VETERINARY VACCINES 115
TABLE 55 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 117
9.2 INJECTABLE VACCINES 117
9.2.1 INJECTABLE VACCINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 117
TABLE 56 INJECTABLE VETERINARY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118
9.3 ORAL VACCINES 118
9.3.1 ORAL VACCINES MAKE IMMUNIZATION EASIER 118
TABLE 57 ORAL VETERINARY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 119
9.4 INTRANASAL/SPRAY VACCINES 120
9.4.1 LOW COST OF INTRANASAL/SPRAY VACCINES TO SUPPORT MARKET GROWTH 120
TABLE 58 INTRANASAL/SPRAY VETERINARY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
10 VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL 121
10.1 INTRODUCTION 122
TABLE 59 VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 122
10.2 VETERINARY HOSPITALS 122
10.2.1 VETERINARY HOSPITALS FORM LARGEST AND FASTEST-GROWING END-USER SEGMENT IN VETERINARY VACCINES MARKET 122
TABLE 60 US: VETERINARY VISIT EXPENSES FOR CATS AND DOGS 123
TABLE 61 VETERINARY VACCINES MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 123

10.3 VETERINARY CLINICS 124
10.3.1 INCREASING NUMBER OF PRIVATE CLINICAL PRACTICES TO SUPPORT MARKET GROWTH 124
TABLE 62 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY, 2019 VS. 2021 124
TABLE 63 VETERINARY VACCINES MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 125
10.4 RETAIL PHARMACIES 125
10.4.1 EASY ACCESSIBILITY TO PHARMACEUTICALS TO SUPPORT MARKET GROWTH 125
TABLE 64 VETERINARY VACCINES MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2027 (USD MILLION) 126
11 VETERINARY VACCINES MARKET, BY REGION 127
11.1 INTRODUCTION 128
TABLE 65 VETERINARY VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 128
11.2 ASIA PACIFIC 128
11.2.1 ASIA PACIFIC: RECESSION IMPACT 129
FIGURE 36 ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT 129
TABLE 66 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 67 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 68 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 69 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 70 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 131
TABLE 71 ASIA PACIFIC: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 72 ASIA PACIFIC: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 73 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 132
TABLE 74 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 132
TABLE 75 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 133
11.2.2 CHINA 133
11.2.2.1 China to dominate Asia Pacific veterinary vaccines market 133
TABLE 76 CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 77 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 78 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 79 CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 135
TABLE 80 CHINA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 81 CHINA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 82 CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 136
TABLE 83 CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 136
TABLE 84 CHINA: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 136
11.2.3 JAPAN 137
11.2.3.1 Increasing expenditure on pet healthcare to drive market growth 137
TABLE 85 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS IN JAPAN (2000 VS. 2030) (THOUSAND METRIC TONS) 137
TABLE 86 JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 87 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 88 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 89 JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 139
TABLE 90 JAPAN: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 91 JAPAN: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 92 JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 140
TABLE 93 JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 140
TABLE 94 JAPAN: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 140
11.2.4 INDIA 141
11.2.4.1 Dearth of veterinarians to restrain market growth 141
TABLE 95 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS IN INDIA (2000 VS. 2030) (THOUSAND METRIC TONS) 141
TABLE 96 INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 97 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 98 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 99 INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 143
TABLE 100 INDIA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 101 INDIA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 102 INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 144
TABLE 103 INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 144
TABLE 104 INDIA: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 144

11.2.5 AUSTRALIA 145
11.2.5.1 Increase in pet ownership to support market growth 145
TABLE 105 AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 106 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 107 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 108 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 146
TABLE 109 AUSTRALIA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 110 AUSTRALIA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 111 AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 147
TABLE 112 AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 147
TABLE 113 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 148
11.2.6 SOUTH KOREA 148
11.2.6.1 Growing companion animal population to drive market growth 148
TABLE 114 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 115 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 116 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 117 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 149
TABLE 118 SOUTH KOREA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 119 SOUTH KOREA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 120 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 150
TABLE 121 SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 151
TABLE 122 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 151
11.2.7 THAILAND 151
11.2.7.1 Growth of pork and poultry industry to drive market 151
TABLE 123 THAILAND: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 124 THAILAND: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 125 THAILAND: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 126 THAILAND: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 153
TABLE 127 THAILAND: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 128 THAILAND: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 129 THAILAND: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 154
TABLE 130 THAILAND: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 154
TABLE 131 THAILAND: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 154
11.2.8 REST OF ASIA PACIFIC 155
TABLE 132 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 133 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 134 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 135 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 156
TABLE 136 REST OF ASIA PACIFIC: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 137 REST OF ASIA PACIFIC: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 138 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 157
TABLE 139 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 157
TABLE 140 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 158
11.3 NORTH AMERICA 158
FIGURE 37 EXPECTED GROWTH IN NUMBER OF VETERINARIANS IN NORTH AMERICA 158
11.3.1 NORTH AMERICA: RECESSION IMPACT 159
FIGURE 38 NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT 159
TABLE 141 NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
TABLE 142 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 143 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 144 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 145 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 161
TABLE 146 NORTH AMERICA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 147 NORTH AMERICA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 148 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 162
TABLE 149 NORTH AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 162
TABLE 150 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 163
11.3.2 US 163
11.3.2.1 US to dominate North American veterinary vaccines market 163
FIGURE 39 US: POPULATION OF DOGS, 2012–2020 (MILLION) 163
FIGURE 40 US: EXPENDITURE ON VET VISITS 164
TABLE 151 HEALTHCARE EXPENDITURE ON COMPANION ANIMALS, 2018 VS. 2020 164
FIGURE 41 INCOME OF VETERINARIANS IN US, 2017–2021 164
FIGURE 42 NUMBER OF VETERINARIANS IN US, 2016–2020 165
TABLE 152 US: NUMBER OF VETERINARIANS IN PRIVATE CLINICAL PRACTICES, 2014–2020 165
TABLE 153 US: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 154 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 155 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 156 US: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 167
TABLE 157 US: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 158 US: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 159 US: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 168
TABLE 160 US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 168
TABLE 161 US: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 168
11.3.3 CANADA 169
11.3.3.1 Rising pet and livestock populations to support market growth 169
FIGURE 43 CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION) 169
TABLE 162 CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 163 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 164 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 165 CANADA: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 171
TABLE 166 CANADA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 167 CANADA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 168 CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 172
TABLE 169 CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 172
TABLE 170 CANADA: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 172
11.4 EUROPE 173
11.4.1 EUROPE: RECESSION IMPACT 173
TABLE 171 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 172 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 173 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 174 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 175 EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 175
TABLE 176 EUROPE: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 177 EUROPE: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 178 EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 176
TABLE 179 EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 177
TABLE 180 EUROPE: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 177
11.4.2 GERMANY 177
11.4.2.1 Germany to dominate European veterinary vaccines market 177
TABLE 181 GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 182 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 183 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 184 GERMANY: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 179
TABLE 185 GERMANY: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 186 GERMANY: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 187 GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 180
TABLE 188 GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 180
TABLE 189 GERMANY: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 181
11.4.3 UK 181
11.4.3.1 Growing pet adoption to drive demand for veterinary vaccines 181
TABLE 190 UK: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 191 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 192 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 193 UK: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 183
TABLE 194 UK: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 195 UK: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 196 UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 184
TABLE 197 UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 184
TABLE 198 UK: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 184
11.4.4 FRANCE 185
11.4.4.1 Rising pet ownership to support market growth 185
TABLE 199 FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 185
TABLE 200 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 201 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 202 FRANCE: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 186
TABLE 203 FRANCE: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 204 FRANCE: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 205 FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 187
TABLE 206 FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 188
TABLE 207 FRANCE: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 188
11.4.5 ITALY 188
11.4.5.1 Increasing outbreaks of diseases to support market growth 188
TABLE 208 ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 209 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 210 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 211 ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 190
TABLE 212 ITALY: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 213 ITALY: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 214 ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 191
TABLE 215 ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 191
TABLE 216 ITALY: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 191
11.4.6 SPAIN 192
11.4.6.1 Increase in number of veterinary practices to drive market growth 192
TABLE 217 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 218 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 219 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 220 SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 193
TABLE 221 SPAIN: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 222 SPAIN: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 223 SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 194
TABLE 224 SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 195
TABLE 225 SPAIN: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 195
11.4.7 REST OF EUROPE 195
TABLE 226 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 227 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 228 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 229 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION) 197
TABLE 230 REST OF EUROPE: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 231 REST OF EUROPE: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 232 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 198
TABLE 233 REST OF EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 198
TABLE 234 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 198

ページTOPに戻る

Table of Contents

Summary

The global veterinary vaccines market is projected to reach USD 10.8 billion by 2027 from USD 8.1 billion in 2022, at a CAGR of 5.9% during the forecast period. In emerging countries such as India and China, the pet insurance industry is in the nascent stage. The increasing disposable incomes and rising pet expenditure are expected to increase the adoption of pet insurance policies and support the veterinary health industry.

Bovine vaccines segment accounted for a larger share of the livestock vaccines market

In 2021, the bovine vaccines segment accounted for a larger share of the livestock vaccines market. This segment is also estimated to grow at a higher CAGR during the forecast period. Growth in this segment can primarily be attributed to the increasing demand for meat and milk and increased awareness about the prevention of diseases in livestock.

The recombinant vaccines will grow at highest CAGR during the forecast period

Based on technology, the recombinant vaccines will grow at highest CAGR during the forecast period. The major advantages offered by recombinant vaccines include the lack of need for adjuvants and the stability offered by these vaccines that allows them to remain viable at ambient temperatures. Also, these vaccines are free from pathogen contamination, exhibit no post-vaccination reactions, and offer higher safety

North America accounted for the second largest share of the global veterinary vaccines market

In 2021, North America accounted for a share of the global veterinary vaccines market. The increasing animal population and growing animal disease prevalence, rising awareness of veterinary vaccines, and the increasing demand for animal products are the major factors that are expected to drive the growth of the veterinary vaccines market in North America. In addition to the increasing healthcare expenditure, there has been a surge in the pet health insurance industry.

The break-up of the profile of primary participants in the veterinary vaccines market:
• By Company Type: Tier 1 – 60%, Tier 2 – 30%, and Tier 3 – 10%
• By Designation: C Level – 30%, Director Level – 50%, Others-20%
• By Region: North America – 45%, Europe – 15%, Asia Pacific – 25%, Middle East – 5%, and Latin America –10%

The prominent players in the veterinary vaccines market include Zoetis, Inc. (US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health (US), Virbac (France).
Research Coverage:
The report analyzes the veterinary vaccines market and aims at estimating the market size and future growth potential of this market based on various segments such as type, disease, technology, route of administration, distribution channel and region. The report also includes a product portfolio matrix of various veterinary vaccines available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall veterinary vaccines market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:

• Analysis of key drivers (growth in the companion animal population, rising incidence of zoonotic diseases, initiatives by various government agencies and animal associations, rising demand for animal-derived food products, growing demand for pet insurance, and rising animal health expenditure), restraints (the high storage cost of vaccines and rising pet care costs), opportunities (technological advancements and untapped emerging markets), and challenges (inadequate surveillance and reporting systems and lack of animal healthcare awareness emerging countries) influencing the growth of the veterinary vaccines market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the veterinary vaccines market
• Market Development: Comprehensive information on the lucrative emerging markets by type, disease, technology, route of administration, distribution channel and region.
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global veterinary veterinary market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players like Zoetis, Inc. (US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health (US), Virbac (France) in the global veterinary vaccines market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets社のPharmaceuticals分野での最新刊レポート

本レポートと同じKEY WORD（veterinary）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

動物用ワクチンの市場：種類（豚、家禽、家畜、コンパニオンアニマル）、技術（生消毒、不活化、毒素）、投与経路（注射、鼻腔内）、流通チャネル（病院、クリニック）-2027年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets社のPharmaceuticals分野での最新刊レポート

本レポートと同じKEY WORD（veterinary）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?